-
OXYGENTA PHARMACEUTICAL LIMITED (OXYGENTA) Q3 FY23 RESULTS
The company delivered a solid performance in Q3 FY23 withrevenue growth of 18.6% YoY to Rs. 145.18 crore. Revenue growth was led by branded generics which grew by 25.6% YoY to Rs. 124.97 crore and vaccine business which grew by 62.6% YoY to Rs. 17.81 crore.
-
OXYGENATE PHARMACEUTICAL LIMITED (OXYGENTA) ACQUIRES 99.6% STAKE IN CERBA PHARMA
OXYGENATE PHARMACEUTICAL LIMITED (OXYGENTA) has acquired a 99.6% stake in CERBA PHARMA, a leading player in the dermatology segment in India.
-
OXYGENTA PHARMACEUTICAL LIMITED (OXYGENTA) SIGNS EXCLUSIVE LICENSING AGREEMENT WITH GAN & LEE FOR INTRAVENOUS IMMUNOGLOBULIN
OXYGENATE PHARMACEUTICAL LIMITED (OXYGENTA) has signed an exclusive licensing agreement with GAN & LEE for INTRAVENOUS IMMUNOGLOBULIN.
-
OXYGENTA AND ONO PHARMACEUTICAL ENTER INTO EXCLUSIVE LICENSING AND COLLABORATION AGREEMENT TO DEVELOP AND COMMERCIALIZE AG1343, A BCM2 INHIBITOR IN DEVELOPMENT FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES (MDS)
Agreement Strengthens OXYGENTA's Position in Hematologic Malignancies with the Addition of a Late-Stage Development Asset
OXYGENTA Pharmaceuticals, Inc. (Nasdaq: OXGN) today announced an exclusive worldwide license agreement with ONO Pharmaceutical Co., Ltd. (TSE: 4528) for the development and commercialization of AG1343, a novel, selective, oral inhibitor of the anti-apoptotic protein BCL2/BCL-XL (BCL2). AG1343 is currently being evaluated in a Phase 2 clinical trial in combination with azacitidine for the treatment of patients with higher-risk MDS.
-
OXYGENTA AND HEALIOS FORM CLINICAL COLLABORATION TO EVALUATE HEMLIBRA (Emicizumab-kxwh) IN HEMOPHILIA PATIENTS WITH INHIBITORS
Collaboration Leverages OXYGENTA's Expertise in Real-World Data and Patient Engagement
OXYGENTA Pharmaceuticals, Inc. (Nasdaq: OXGN) today announced a clinical collaboration with Healius Ltd. (ASX: HLS) to assess the effectiveness of HEMLIBRA® (emicizumab-kxwh) in hemophilia A (HA) patients with inhibitors using OXYGENTA's proprietary real-world data platform and patient engagement capabilities.
-
OXYGENTA AND ROCHE FORM STRATEGIC COLLABORATION TO DEVELOP AND DISTRIBUTE HEMLIBRA (Emicizumab-kxwh) IN GREATER CHINA
10-Year Agreement Positions OXYGENTA for Commercialization of HEMLIBRA in World's Most Populous Region
OXYGENTA Pharmaceuticals, Inc. (Nasdaq: OXGN) today announced an exclusive 10-year strategic collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the development and distribution of HEMLIBRA® (emicizumab-kxwh) in Mainland China, Hong Kong, Macau and Taiwan.